2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5138 Post-transplant time to relapse for FLT3-ITD, KMT2A-rearranged, or NUP98-rearranged AML

Helen Tian, Todd A. Alonzo, PhD2, Jim Wang3, Caitlin W. Elgarten, MD4, Franziska Wachter, MD5, Vasant Chinnabhandar, MD, FRACP6, Rhonda E. Ries, MA7, Alan S. Gamis, MD8, Richard Aplenc I, MD, PhD9, Todd Cooper I, DO10, Xiaotu Ma, PhD11, Katherine Tarlock I, MD12, Soheil Meshinchi, MD, PhD13, Shalini Shenoy, MD14, Jessica A. Pollard I, MD15, John Horan, MD16, Joseph Chewning, MD17, Benjamin J. Huang, MD18
1 University of California, San Francisco, San Francisco, California, United States
2 University of Southern California, Los Angeles, California, United States
3 Children's Oncology Group, Arcadia, California, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Dana Farber Cancer Institute, Boston, Massachusetts, United States
6 Perth Children's Hospital, Perth, Australia
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Children's Mercy Hospital, Kansas City, Missouri, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
10 Seattle Children’s Hospital, Seattle, Washington, United States
11 St Jude Children's Research Hospital, Memphis, Tennessee, United States
12 Seattle Children’s Hospital, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 Washington University, St. Louis, Missouri, United States
15 Dana Farber Cancer Institute, Boston, Massachusetts, United States
16 University of Rochester Medical Center, Rochester, New York, United States
17 University of Alabama at Birmingham, Birmingham, Alabama, United States
18 University of California, San Francisco, San Francisco, California, United States

Introduction: Targeted therapies for acute myeloid leukemia (AML) have demonstrated efficacy for patients diagnosed with specific AML genetic subtypes. These targeted therapies are under investigation following consolidative hematopoietic stem and progenitor transplant (HSCT) or bone marrow transplant (BMT). Specifically, BCL2, FLT3, IDH1/2, and menin inhibitors are actively undergoing evaluation as post-transplant maintenance therapies for patients at high-risk for relapse, with recent FLT3 inhibitor results establishing the overall promise of this approach. Within pediatric AML, genetic subtypes being considered for post-transplant maintenance therapy include FLT3-ITD AML (FLT3 inhibitors), KMT2A-rearranged AML (menin inhibitors), and NUP98-rearranged AML (menin inhibitors). The optimal approach to maintenance therapy for these subsets of patients, such as timing and duration, has not been determined. Often these decisions are complicated by the need to balance infectious and/or transplant-related complications (e.g., graft versus host disease) with the risk of leukemia relapse. Therefore, a better understanding regarding the time to relapse for these genetic subtypes of pediatric AML would better inform these decisions. Here, we report the cumulative incidence of relapse at days +30, +100, and +365 post-transplant and the long-term outcomes for FLT3-ITD, KMT2A-rearranged (KMT2Ar), and NUP98-rearranged (NUP98r) AML.

Methods: Clinical and biological data were combined from patients enrolled on two consecutive COG phase 3 trials for de novo AML: AAML0531 (NCT00372593) and AAML1031 (NCT01371981). Each protocol was approved by the National Cancer Institute's central institutional review board (IRB) and the local IRB for each participating institution. Patients and/or families provided informed consent or assent as appropriate. Whole-genome sequencing and transcriptome sequencing (RNA-seq) were performed on diagnostic samples and variant/fusion calling was performed as previously described. Of the 2,024 eligible patients enrolled on AAML0531 and AAML1031, 1,770 (87%) had sufficient cytogenetic/molecular and measurable residual disease (MRD) data to assess risk according to the contemporary risk stratification schema. Of these 1,770 patients, 1,445 (81%) achieved morphologic first complete remission (CR1) and received the three chemotherapy courses that preceded HSCT (if prescribed). Of these 1,445 patients, 219 (15%) patients underwent HSCT in CR1. We excluded patients who received sorafenib maintenance on AAML1031, leaving 171 remaining patients. Of these 171 patients, 15 were NUP98r, 15 were KMT2Ar (with high-risk fusion partners, such as MLLT10, MLLT4 or AFDN, MLLT2 or AFF1, MLLT1 or ENL), 42 were FLT3-ITD, and 99 were other genetic subtypes. Relapse was defined using AAML0531 and AAML1031 criteria, which included morphologic relapse (≥ 5% blasts in the bone marrow), reappearance of genetic or molecular abnormalities (confirmed on two independent bone marrow evaluations), or cytologically proven extramedullary disease.

Results: Cumulative incidence of relapse (CIR) at day +30 was 0%, 6.7%, 0%, and 2% for NUP98r, KMT2Ar, FLT3-ITD, and other AML, respectively. CIR at day +100 was 13.3%, 20%, 7.1%, and 7.1% for NUP98r, KMT2Ar, FLT3-ITD, and other AML, respectively. CIR at day +365 was 60%, 46.7%, 23.8%, and 20.2% for NUP98r, KMT2Ar, FLT3-ITD, and other AML, respectively. Five-year overall survival (OS) was 62.2%, 40%, 58.8%, and 61% for NUP98r, KMT2Ar, FLT3-ITD, and other AML, respectively (p = 0.334). Five-year disease free survival (DFS) was 33.3%, 33.3%, 49.8%, and 60.1% for NUP98r, KMT2Ar, FLT3-ITD, and other AML, respectively (p = 0.017). Five-year CIR was 66.7%, 53.3%, 40.7%, and 27.6% for NUP98r, KMT2Ar, FLT3-ITD, and other AML, respectively (p = 0.003).

Conclusions: Taken together, our data provide short-term relapse rates and long-term outcomes for targetable subtypes of pediatric AML, which will inform strategies for post-transplant maintenance therapy (e.g., timing of initiation and duration) and guide post-transplant clinical trial design. Our reported relapse rates suggest that many patients may benefit from early initiation of targeted maintenance therapies and that early molecular monitoring will likely impact the optimal timing of initiation. Additional future studies are needed to determine the impact of post-transplant maintenance therapy interventions.

Helen Tian: No relevant conflicts of interest to declare.